On Monday, Shares of Microsoft Corporation (NASDAQ:MSFT), lost -0.80% to $47.37.
At Adobe Summit in London, Adobe’s annual European Digital Marketing conference, Adobe and Microsoft Corporation, declared a planned partnership that will redefine how enterprises manage their marketing, sales and services to better engage with customers across all touch points. The partnership will comprise the integration of Adobe’s industry leading Marketing Cloud Solutions with Microsoft’s best-in-class Dynamics CRM and allow brands to deliver experiences that take all customer engagements into account – from reach and acquisition to retention and loyalty. This new integration will assist eliminate frustrating customer experiences that result when marketing, sales and service interactions are siloed.
“Assisting our customers reinvent productivity and business processes is one of our top priorities. Partnering with Adobe enables us to deliver a comprehensive set of customer engagement processes to enterprise customers to assist them be more productive and better engage with their customers,” said Kirill Tatarinov, executive vice president, Microsoft Business Solutions. “The integration of our industry-leading Dynamics CRM solution with Adobe Marketing Cloud will enable business professionals to maximize their investment in technology and deliver breakthroughs in marketing, sales and customer care.”
“Adobe and Microsoft are creating the industry’s first large-scale solution for connecting the customer experience across all touch points,” said Brad Rencher, senior vice president and general manager, Digital Marketing Business at Adobe. “We are making it possible for the long-held promise of the customer-centric enterprise to become a data-driven reality.”
Microsoft Corporation develops, licenses, markets, and supports software, services, and devices worldwide. The company’s Devices and Consumer (D&C) Licensing segment licenses Windows operating system and related software; Microsoft Office for consumers; and Windows Phone operating system.
Shares of Hemispherx Biopharma, Inc. (NYSEMKT:HEB), inclined 2.77% to $0.26, during its last trading session.
Hemispherx Biopharma, declared that its European partner, Hemispherx Biopharma Europe N.V./S.A., received formal notification from the European Commission [EU/3/15/1480-EMA/OD/310/14] approving its Orphan Medicinal Product Application for Ampligen(R), an experimental therapeutic, to treat Ebola Virus Disease (EVD). Thomas K. Equels, Executive Vice Chairman, states, “European Medicines Agency designation of Ampligen(R)/rintatolimod as an orphan drug is an important achievement in our path seeking commercial approval of Ampligen(R) as a prophylactic and early onset therapeutic for Ebola and other lethal viral diseases.
Orphan drug designation promotes the clinical development of drugs that target rare life-threatening conditions and which are predictable to provide noteworthy therapeutic advantage over any existing treatments and comprises some tropical diseases primarily found in developing nations as is the case for EVD.
Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States.
At the end of Monday’s trade, Shares of Boston Scientific Corporation (NYSE:BSX), lost -0.23% to $17.47.
Boston Scientific Corporation, declared that key data from 42 abstracts will be featured at the 36th Annual Scientific Sessions of the Heart Rhythm Society (HRS) in Boston on May 13-16.
Following recent successes – counting the U.S. Food and Drug Administration (FDA) approvals of the WATCHMAN™ Left Atrial Appendage Closure Device and the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System, in addition to the commercial roll-out of the EMBLEM S-ICD System in Europe and of the Rhythmia™ Mapping System in the United States – the company’s planned data presentations at HRS will underscore:
- The long-term safety and efficacy of the industry’s only Subcutaneous Implantable Defibrillator (S-ICD);
- Multiple sources of device longevity data proving the industry-leading performance of the EnduraLife™ Battery Technology in Boston Scientific defibrillators, as well data highlighting premature replacement procedures due to early battery depletion of devices without this battery technology
- The beneficial economic impact the WATCHMAN Device is projected to have on Medicare in comparison to warfarin and aspirin for stroke risk reduction in indicated patients with non-valvular atrial fibrillation;
- The quality of the mapping data obtained in the initial human experiences using the high-resolution Rhythmia Mapping System to guide cardiac ablation procedures.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Administration, and MedSurg.
Finally, Cabot Oil & Gas Corporation (NYSE:COG), ended its last trade with -0.26% loss, and closed at $34.97.
On April 24, Cabot Oil & Gas Corporation, stated its financial and operating results for the first quarter of 2015. Highlights for the quarter when contrast to the first quarter of 2014 comprise:
- Production of 171.4 billion cubic feet equivalent (Bcfe), an enhance of 43 percent
- Liquids production (crude oil/condensate/natural gas liquids) of 1.6 million barrels (Mmbbls), an enhance of 132 percent
- Total unit costs (counting financing) of $2.33 per thousand cubic feet equivalent (Mcfe), a 12 percent improvement
- Total cash unit costs (counting financing) of $1.22 per Mcfe, a 10 percent improvement
- Subsequent to the end of the first quarter, the Company closed an amendment to its revolving credit facility that raised the borrowing base to $3.4 billion; raised the lenders’ commitments to $1.8 billion; extended the maturity date three additional years; and reduced the drawn and undrawn pricing based on current leverage levels. As of the end of the first quarter, the Company had $265 million of borrowings outstanding under its revolving credit facility
Cabot Oil & Gas Corporation, an independent oil and gas company, develops, exploits, explores for, produces, and markets natural gas, oil, and natural gas liquids in the United States. The company primarily focuses on the Marcellus Shale in northeast Pennsylvania with about 200,000 net acres in the dry gas window of the play; and the Eagle Ford Shale in south Texas with about 89,000 net acres in the oil window of the play.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
